The Russian retail pharmaceutical market, which reached a volume of 1.89 trillion rubles (+15.8%) in 2025, is undergoing a radical shift in leadership. This is evidenced by the data from the RNC Pharma analytical report “Retail Segment of the Russian Pharmaceutical Market. Results of 2025”. For the first time in many years, the Nizhpharm group has displaced the German concern Bayer from the top spot in the revenue ranking. At the same time, Russian companies are strengthening their dominance in physical volume terms, with Ozon Pharmaceuticals demonstrating record growth rates and threatening the position of the leader — Pharmstandard.
General Market Indicators
According to RNC Pharma, the retail market demonstrated the following results in 2025:
- 1.89 trillion RUB — sales volume in monetary terms (in retail prices, VAT included). Growth compared to 2024 amounted to +15.8%.
- 4.93 billion packs — sales volume in physical terms. The market dynamics amounted to +1.8%.
Revenue Rating: Reshuffling of Manufacturing Corporations
The sensation of the year in the corporate segment was the change of the leader in sales volume in monetary terms. The Nizhpharm Group rose to the first line of the rating. The long-standing leader — the Bayer concern — moved to the second position.
Nizhpharm’s success is driven by a powerful portfolio, including cardiology drugs (the “Edarbi” brand entered the market’s TOP-5 with a growth of +26%) and nasal products (the “Snoop” line holds 7.9% in its category).
The top ten revenue leaders also include major international players: Servier, Abbott, Sanofi, and KRKA. Among Russian companies, besides the leader, Ozon Pharmaceuticals demonstrates impressive dynamics (+38%).
Table 1. TOP-10 Corporations by Sales Volume in Monetary Terms (2025)
| No. | Corporation | Market Share (Rub), % | Dynamics vs 2024, % |
|---|---|---|---|
| 1 | Nizhpharm Group | 3.29 | +9 |
| 2 | Bayer Healthcare | 3.29 | +3 |
| 3 | Servier | 3.18 | +17 |
| 4 | Abbott | 3.09 | +18 |
| 5 | Sanofi | 2.67 | +14 |
| 6 | KRKA | 2.66 | +16 |
| 7 | Teva | 2.61 | +13 |
| 8 | Ozon Pharmaceuticals | 2.59 | +38 |
| 9 | Binnopharm Group | 2.50 | +12 |
| 10 | Otisipharm | 2.39 | +6 |
Source: RNC Pharma
Volume Rating: The Race of Russian Factories
In physical terms, Ozon Pharmaceuticals is closing the gap with Pharmstandard, demonstrating growth rates significantly outpacing the market (+19% versus the market average of 1.8%). The rating leader — Pharmstandard — is losing volume (-9%), which is associated with a decrease in demand for traditional low-cost drugs.
Table 2. TOP-10 Corporations by Sales Volume in Physical Terms (2025)
| No. | Corporation | Share (Packs), % | Dynamics, % | Comment |
|---|---|---|---|---|
| 1 | Pharmstandard | 5.22 | -9 | Retains leadership but loses market share due to declining demand for old brands (Citramon, Acetylsalicylic acid). |
| 2 | Ozon Pharmaceuticals | 4.68 | +19 | Main growth driver in the TOP 10. Aggressive expansion of the generic portfolio. |
| 3 | Renewal (Obnovlenie) | 3.45 | +6 | Stable growth due to branding of traditional drugs (Naphthyzinum, Paracetamol). |
| 4 | Nizhpharm Group | 3.43 | -4 | The revenue rating leader takes 4th place in terms of packs. |
| 5 | Otisipharm | 3.22 | -3 | Decrease in unit sales is compensated by the high value of brands (Pentalgin, Arbidol). |
| 6 | Binnopharm Group | 3.16 | -4 | A major player in the antibiotics segment (Ceftriaxone). |
| 7 | Teva | 2.81 | +6 | Best dynamics among foreign companies in the volume TOP 10. |
| 8 | Akrikhin | 2.25 | +2 | Moderate growth. |
| 9 | Dr. Reddy’s | 2.05 | +6 | Successful growth of the Indian manufacturer. |
| 10 | Sanofi | 1.93 | +4 | Maintains position at the tail of the top ten. |
Source: RNC Pharma
Study Results
- Polarization of strategies: Revenue leaders (Nizhpharm, Bayer, AstraZeneca) rely on expensive prescription drugs and innovative solutions. For example, the “Forsiga” brand showed a growth of +54%, and “Edarbi” +26%. At the same time, volume leaders (Ozon Pharmaceuticals, Renewal) win due to “bulk” — mass production of affordable generics (Omeprazole, Bisoprolol), replacing cheap competitor drugs washing out of the market.
- The “Ozon” Effect: The growth of Ozon Pharmaceuticals by 19% in physical terms against a stagnating market (where the average dynamic is +1.8%) indicates a large-scale redistribution of shares. The company successfully captures consumers from other manufacturers by offering a wider product line.
- Crisis of old portfolios: Pharmstandard (-9% in packs) and Binnopharm (-4%) face falling demand for traditional drugs (Citramon, Analgin, simple antibiotics), forcing them to revise their assortment policy.
2025 recorded a trend towards consolidation. In monetary terms, the market was led by the localized group Nizhpharm, symbolizing the success of the deep localization strategy. In terms of packs, there is a fierce battle for the shelf, in which Ozon’s aggressive tactics are changing the balance of power in the economy segment.
